Drug intelligence / Profile preview

RLD2203

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules

Overview

RLD2203 is a small molecule drug developed by Hanmi Pharmaceutical. It has been studied in multiple Phase 1 clinical trials, primarily to evaluate its pharmacokinetic and safety profile, both alone and in combination with another investigational agent, RLD2202. The studies have focused on healthy adult volunteers to assess drug-drug interactions and tolerability. The specific mechanism of action, molecular target(s), therapeutic area(s), and active indication(s) for RLD2203 have not been publicly disclosed as of the latest available data[1][2][3].

Beyond the preview

Go deeper on RLD2203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RLD2203.

Explore the full profile